{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:20:07Z","timestamp":1783455607840,"version":"3.55.0"},"reference-count":127,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>\n                    Despite therapeutic advances, breast tumors treated with definitive intent can recur, and metastatic breast cancer (MBC) remains incurable. Hormone receptor\u2013positive, HER2-negative (HR+\/HER2\u2013) breast cancer is driven by estrogen receptor (ER) signaling, and endocrine therapy (ET), frequently combined with CDK4\/6 inhibition, is a key treatment of endocrine-sensitive disease. Endocrine resistance inevitably develops in the metastatic setting, often mediated by acquired\n                    <jats:italic toggle=\"yes\">ESR1<\/jats:italic>\n                    mutations that promote ligand-independent ER activation and reduce sensitivity to standard antiestrogens. Multiple next-generation ER-directed therapies are being developed to overcome resistance and improve outcomes, several of which are entering practice. This review examines clinical and translational evidence supporting emerging ER-targeted monotherapies and combination strategies across the metastatic and curative-intent settings. Pivotal trials demonstrate that oral selective estrogen receptor degraders (SERDs) and other novel ER-directed agents enhance anticancer activity, particularly for\n                    <jats:italic toggle=\"yes\">ESR1<\/jats:italic>\n                    -mutant disease. Multidrug regimens pairing oral SERDs with CDK4\/6 inhibitors, or with agents targeting the PI3K\/AKT pathway, have shown encouraging efficacy in endocrine-refractory MBC, and these advances are reshaping management paradigms. Trial results and regulatory approvals are contextualized by outstanding questions surrounding the adoption of newer endocrine therapies. Their optimal integration and sequencing in practice remain uncertain, and for tumors harboring dual\n                    <jats:italic toggle=\"yes\">ESR1<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                    mutations, with multiple biomarker-guided options available, the best treatment strategies are unclear. Furthermore, dynamic monitoring of circulating tumor DNA for acquired\n                    <jats:italic toggle=\"yes\">ESR1<\/jats:italic>\n                    mutations could enable early therapeutic switching to a more active agent, but limitations remain for the broader adoption of this approach. With several oral SERDs emerging contemporaneously, data are needed to assess their relative efficacy, safety, and potential interchangeability. As the ET landscape grows increasingly complex, integrating clinical-genomic biomarkers with evidence from trials and real-world experience will be critical to optimize personalized care.\n                  <\/jats:p>","DOI":"10.1200\/op-26-00199","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:59:09Z","timestamp":1783454349000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-0437","authenticated-orcid":true,"given":"Maxwell R.","family":"Lloyd","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Shatsky","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Love","sequence":"additional","affiliation":[{"name":"Research to Practice, Key Biscayne, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-4708","authenticated-orcid":true,"given":"Seth A.","family":"Wander","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21754"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194689"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2025.106729"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9573"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.11.056"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-017-0046-2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.06.026"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510809200"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.01.016"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601630"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1487"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2947"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30165-3"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.013"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.005"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2332"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.08.008"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-4037"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3061"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2018-01095"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1171"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.004"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0224"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.117"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0851-4"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1229"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1523"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11579"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0264"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3276"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221113694"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00935-6"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176424"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0694"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2561"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2608"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00847"},{"key":"e_1_3_4_52_2","volume-title":"FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer","author":"Center for Drug Evaluation and Research","year":"2023","unstructured":"Center for Drug Evaluation and Research: FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. FDA, 2023"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS3-01"},{"key":"e_1_3_4_55_2","article-title":"Real-world outcomes of elacestrant in ER+, HER2-ESR1-mutant metastatic breast cancer","author":"Rugo HS","year":"2025","unstructured":"Rugo HS, Kaklamani V, McArthur H, et al: Real-world outcomes of elacestrant in ER+, HER2-ESR1-mutant metastatic breast cancer. Clin Cancer Res, 2025","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3033"},{"key":"e_1_3_4_57_2","volume-title":"FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer","author":"Center for Drug Evaluation and Research","year":"2025","unstructured":"Center for Drug Evaluation and Research: FDA Approves Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. FDA, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410858"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.018"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00387-5"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01500"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02746"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01160"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105057"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-GS1-10"},{"key":"e_1_3_4_66_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS619","article-title":"ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study","volume":"43","author":"Bardia A","year":"2025","unstructured":"Bardia A, Kaklamani VG, O\u2019Shaughnessy J, et al: ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. J Clin Oncol 43, 2025 (suppl 16; abstr TPS619)","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-OT1-01-02"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2459548"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02203-6"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-44"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1148"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181e84bb4"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808692"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3104"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02049-y"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2608863"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.433"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.07.007"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2023.07.005"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P4-04-28"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1039"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4442"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0143"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00284-4"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.011"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF7-02"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu456"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796"},{"issue":"5","key":"e_1_3_4_91_2","first-page":"OT2","article-title":"Abstract OT2-01-03: Elevate: A phase 1b\/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC)","volume":"83","author":"Rugo H","year":"2023","unstructured":"Rugo H, Bardia A, Cort\u00e9s J, et al: Abstract OT2-01-03: Elevate: A phase 1b\/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC). Cancer Res 83:OT2-01-03-OT2-01-03, 2023 (suppl 5)","journal-title":"Cancer Res"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF7-01"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3103"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1127"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.256313"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P5-07-28"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-P6-10-07"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2025.2537412"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO3-18-06"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1079"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.015"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1086"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS7-02"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF7-04"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.026"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00555-1"},{"key":"e_1_3_4_108_2","first-page":"329","article-title":"Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer","volume":"27","author":"Cabel L","year":"2025","unstructured":"Cabel L, Berger F, Bachelot T, et al: Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. Ann Oncol 27:329-340, 2025","journal-title":"Ann Oncol"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502929"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF7-03"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00894-4"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02733"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO3-05-08"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS1-08-28"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS1-11-15"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1073"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e13097"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.018"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-GS3-09"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF7-05"},{"key":"e_1_3_4_121_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1069","article-title":"Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician\u2019s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2\u2013 aBC)","volume":"41","author":"Collier A","year":"2023","unstructured":"Collier A, Chavez Mac Gregor M, Hilz S, et al: Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician\u2019s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2\u2013 aBC). J Clin Oncol 41, 2023 (suppl 16; abstr 1069)","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1101"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.006"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116140"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03060-0"},{"key":"e_1_3_4_126_2","article-title":"FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","author":"Center for Drug Evaluation and Research","year":"2026","unstructured":"Center for Drug Evaluation and Research. FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA. 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast","journal-title":"FDA"},{"key":"e_1_3_4_127_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1006","article-title":"Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor\u2013positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2\u2212 LA\/mBC): Primary analysis of the phase III persevERA BC trial","volume":"44","author":"Turner NC","year":"2026","unstructured":"Turner NC, Jhaveri KL, Bardia A, et al: Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor\u2013positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2\u2212 LA\/mBC): Primary analysis of the phase III persevERA BC trial. J Clin Oncol 44, 2026 (suppl 17; abstr LBA1006)","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1008"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:59:12Z","timestamp":1783454352000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":127,"alternative-id":["10.1200\/OP-26-00199"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00199","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2026-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00199"}}